A compound according to Formula I: wherein Cy is - monocyclic C 3-7 cycloalkyl optionally substituted with one or more independently selected R 3 , or - 4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one or more independently selected R 3 ; R 1 is - H, - -SO 3 H, - -P(=O)(OH) 2 , - C 1-4 alkyl, - -C(=O)-(4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O), or - -C(=O)C 1-6 alkyl, which C 1-6 alkyl is optionally substituted with one or more independently selected R 4 groups; R 2 is H or C 1-4 alkyl; each R 3 is independently selected from: - OH, - =O, - halo, and - C 1-4 alkyl; each R 4 is independently selected from: - -NR 5a R 5b , - -C(=O)OH, - 4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one or more independently selected C 1-4 alkyl, and - -NHC(=O)-C 1-4 alkyl-NH 2 ; and R 5a and R 5b are independently H or C 1-4 alkyl; or a pharmaceutically acceptable salt or a solvate or the salt of a solvate thereof. Cy is - monocyclic C 3-7 cycloalkyl optionally substituted with one or more independently selected R 3 , or - 4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one or more independently selected R 3 ; - monocyclic C 3-7 cycloalkyl optionally substituted with one or more independently selected R 3 , or - 4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one or more independently selected R 3 ; R 1 is - H, - -SO 3 H, - -P(=O)(OH) 2 , - C 1-4 alkyl, - -C(=O)-(4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O), or - -C(=O)C 1-6 alkyl, which C 1-6 alkyl is optionally substituted with one or more independently selected R 4 groups; - H, - -SO 3 H, - -P(=O)(OH) 2 , - C 1-4 alkyl, - -C(=O)-(4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O), or - -C(=O)C 1-6 alkyl, which C 1-6 alkyl is optionally substituted with one or more independently selected R 4 groups; R 2 is H or C 1-4 alkyl; each R 3 is independently selected from: - OH, - =O, - halo, and - C 1-4 alkyl; - OH, - =O, - halo, and - C 1-4 alkyl; each R 4 is independently selected from: - -NR 5a R 5b , - -C(=O)OH, - 4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one or more independently selected C 1-4 alkyl, and - -NHC(=O)-C 1-4 alkyl-NH 2 ; and - -NR 5a R 5b , - -C(=O)OH, - 4-7 membered monocyclic heterocycloalkyl comprising one or two heteroatoms independently selected from N, S, and O, optionally substituted with one or more independently selected C 1-4 alkyl, and - -NHC(=O)-C 1-4 alkyl-NH 2 ; and R 5a and R 5b are independently H or C 1-4 alkyl; or a pharmaceutically acceptable salt or a solvate or the salt of a solvate thereof. <EOS>